CCL2 and ovarian carcinoma: Furthermore, CCL-2 activates the P38-MAPK pathway in cancer cells, and high expression of the CCL-2 receptor CCR-2 has been shown to be a prognostic marker for overall and progression-free survival in ovarian cancer (34).